TARO-FAMPRIDINE 10 MG — DIN 02482398
FAMPRIDINE : 10 MG · TARO PHARMACEUTICALS INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is TARO-FAMPRIDINE?
TARO-FAMPRIDINE 10 MG contains FAMPRIDINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02482398, held by TARO PHARMACEUTICALS INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Nov-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-FAMPRIDINE used for?
Symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5-7).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fampridine cost around the world?
Fampridine is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 4 | CZK███.██ |
| Iceland | max wholesale | 3 | 4 | ISK███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
23 pack listings across 20 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Fampridine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fampridine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Fampridine, across 4 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACORDA THERAPEUTICS IRELAND LIMITED | 1 | 1 | FAMPYRA | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-FAMPRIDINE | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 1 | 1 | TARO-FAMPRIDINE | Sourceable in Canada |
| APOTEX INC | 1 | 0 | APO-FAMPRIDINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Blisters of 14 tablets (cartons of 28 or 56); Bottles of 14 tablets (cartons of 28 or 56). |
| Storage | Not explicitly detailed in provided text snippet (Section 11 not fully visible), but typically store at room temperature. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fampridine |
|---|---|
| ATC code | N07XX07 |
| AHFS class | 92:56.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02482398 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2482398 |
| Brand name | TARO-FAMPRIDINE |
| Generic / active ingredient | FAMPRIDINE : 10 MG |
| Market authorization holder | TARO PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | N07XX07 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N07XX |
| Current status | MARKETED |
| Status date | 24-Nov-2020 |
| Original market date | 2020-11-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended dose is one 10 mg tablet twice daily, taken 12 hours apart without food. Tablets must be swallowed whole. Initial prescription should not exceed 4 weeks to assess benefit.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to fampridine; concurrent use of other fampridine forms; moderate/severe renal impairment (CrCl <50mL/min); history of seizure; concurrent use of OCT2 inhibitors (e.g. cimetidine).
Warnings and precautions
Dose-dependent seizure risk; do not exceed 10mg BID. Risk of hypersensitivity/anaphylaxis. Increased risk of falls due to dizziness. Monitor renal function. Discontinue if seizure occurs.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FAMPYRA | 10 MG | TABLET (EXTENDED-RELEASE) | ACORDA THERAPEUTICS IRELAND LIMITED | MARKETED | 02379910 |
| PMS-FAMPRIDINE | 10 MG | TABLET (EXTENDED-RELEASE) | PHARMASCIENCE INC | MARKETED | 02496216 |
| APO-FAMPRIDINE | 10 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | APPROVED | 02491672 |
2 · Same class — other molecules in ATC N07XX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fampridine | APO-FAMPRIDINE · FAMPYRA · PMS-FAMPRIDINE · TARO-FAMPRIDINE | 4 | 3 | Yes |
| Tetrabenazine | APO-TETRABENAZINE · NITOMAN · PMS-TETRABENAZINE · TETRABENAZINE TABLETS | 4 | 3 | Yes |
| Riluzole | APO-RILUZOLE · MYLAN-RILUZOLE · RILUTEK | 3 | 3 | Yes |
| Amifampridine | FIRDAPSE · RUZURGI | 2 | 2 | Yes |
| Hydroxybutyric Acid | XYREM · XYWAV | 2 | 2 | Yes |
| Pitolisant | WAKIX | 2 | 2 | Yes |
| Tafamidis | VYNDAMAX · VYNDAQEL | 2 | 2 | Yes |
| Edaravone | RADICAVA | 2 | 1 | Yes |
| Trofinetide | DAYBUE | 1 | 1 | Yes |
| Eplontersen | WAINUA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TARO-FAMPRIDINE called?
The same molecule, Fampridine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Fampyra | Latin | Bahrain, Czechia, Iceland, Romania, South Africa |
| Fampyra (Lyfjaver) | Latin | Iceland |
| FAMPRIDIN SANDOZ | Latin | Czechia |
| FAMPRIDINE TEVA | Latin | Czechia |
| Fampyra (Heilsa) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.